Content about Dr. Reddy's Laboratories

January 3, 2013

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

November 28, 2012

Dr. Reddy's Labs has appointed a new CFO and head of its North America business, the generic drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has appointed a new CFO and head of its North America business, the generic drug maker said.

Dr. Reddy's said Umang Vohra will take over the role of EVP and head of generics for North America, starting in January 2013. Vohra has been CFO of Dr. Reddy's for the past four years.

Saumen Chakraborty will take over as CFO of Dr. Reddy's following Vohra's reappointment. Chakraborty is currently president and global head of quality, human resources, information technology and business process excellence.

November 19, 2012

Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

Dr. Reddy's announced the launch of sildenafil tablets in the 20 mg strength in 90-count bottles. The drug is a generic version of Pfizer's Revatio.

Revatio had sales of $338.67 million during the 12-month period ended in September, according to IMS Health.

November 15, 2012

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


October 9, 2012

Drug maker Dr. Reddy’s Labs has launched a generic antibiotic drug, the company said. The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension.

Dr. Reddy's launches antibiotics

September 27, 2012

Dr. Reddy's Labs has launched a generic drug for treating asthma and allergies, and preventing bronchospasm during exercise, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating asthma and allergies, and preventing bronchospasm during exercise, the company said.

The Indian company announced the launch of montelukast sodium oral granules in the 4-mg strength in unit-dose cartons of 30 packets.

The drug is a version of Merck's Singulair oral granules, which had sales of about $61 million during the 12-month period ended in July, according to IMS Health.

September 20, 2012

Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

HYDERABAD, India — Drug maker Dr. Reddy's Labs has launched a generic antibiotic drug, the company said Thursday.

The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension. The tablets are being launched in the 500-mg and 875-mg strengths, while the capsules are in the 250-mg and 500-mg strengths, and the oral suspension is in the 125-mg-, 200-mg-, 250-mg- and 400-mg-per-5-mL strengths.

September 18, 2012

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals.

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals — reducing costs for health plans, payers and patients; scrambling drug makers’ balance sheets; and potentially boosting both drug utilization and adherence rates as reduced out-of-pocket costs induce more patients to fill their prescriptions.


September 11, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

Dr. Reddy's announced the launch of metoprolol succinate extended-release tablets in the 25-mg, 50-mg, 100-mg and 200-mg strengths. The drug will be available in bottle counts of 100 and 500.

The drug is a generic version of AstraZeneca's Toprol-XL, branded and generic versions of which had sales of about $1.13 billion during the 12-month period that ended in June, according to IMS Health.

August 17, 2012

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries.

The U.S. healthcare system presents a paradox: It’s the most expensive system in the world, and yet it produces among the worst results among developed countries. According to the most recent report from the National Health Expenditure Accounts, spending on health care reached $2.6 trillion in 2010, or more than $8,400 per person and around 18% of the country’s gross domestic product.


August 6, 2012

The Food and Drug Administration has approved several generic versions of a drug used to treat asthma and allergies, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved several generic versions of a drug used to treat asthma and allergies, the agency said Friday.

The FDA announced the approval of montelukast sodium, a drug indicated for controlling asthma symptoms and relieving indoor and outdoor allergies.

The drug is a generic version of Merck's Singulair, which had sales of $4.6 billion in 2011, according to IMS Health.

July 18, 2012

Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

The company announced Wednesday the launch of atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Lipitor, which had sales of slightly more than $8 billion during the 12-month period ended in March, according to IMS Health.

July 2, 2012

Dr. Reddy's has launched a drug designed to prevent and treat osteoporosis.

HYDERABAD, India — Dr. Reddy's has launched a drug designed to prevent and treat osteoporosis.

The generic drug maker launched ibandronate sodium tablets in the 150-mg strength, following approval by the Food and Drug Administration for the drug maker's abbreviated new drug application. The drug is a generic version of Boniva.

The branded drug and generic versions had U.S. sales of approximately $486 million during the 12-month period ended in March, according to IMS Health.

June 7, 2012

Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug for treating Parkinson's disease, the company said Thursday.

Dr. Reddy's introduced ropinirole hydrochloride extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths. The 2-mg, 4-mg and 6-mg strengths will be available in 30- and 90-count bottle sizes, while the other two strengths will be available in 30-count bottles.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of $58 million during the 12-month period ended in March, according to IMS Health.

June 6, 2012

A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

May 21, 2012

Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular over-the-counter drug for treating heartburn, the company said Monday.

Dr. Reddy's announced the launch of lansoprazole delayed-release capsules in the 15-mg strength in pack sizes of 14, 28 and 42. The drug is a generic version of Novartis Consumer Health's Prevacid 24 HR capsule brand, which had sales of $115 million during the 12-month period ended in March, according to SymphonyIRI InfoScan Reviews.

May 18, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.

April 24, 2012

Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of an Eli Lilly drug used to treat psychiatric disorders, the company said Tuesday.

Dr. Reddy's announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg and 15-mg strengths.

The drug is a generic version of Zyprexa, used to treat schizophrenia and bipolar disorder. Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

March 5, 2012

Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's has launched a drug designed to treat bipolar disorder and schizophrenia, the company said.

The company announced the launch of ziprasidone hydrochloride capsules in the 20-mg, 40-mg, 60-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Geodon, which had sales of $1.34 billion in 2011, according to IMS Health.

February 21, 2012

A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

MUMBAI, India — A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

In a lawsuit filed in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries and Teva Pharmaceutical Industries, Wyeth Pharmaceuticals said it estimated that it suffered damages of $960 million from Sun's and Teva's launches of generic versions of the gastroesophageal reflux disease drug Protonix (pantoprazole).

January 20, 2012

It has become a perennial issue, and one that is likely to crop up at least once this year: patent settlements.


It has become a perennial issue, and one that is likely to crop up at least once this year: patent settlements.


January 20, 2012

With the patent cliff and subsequent innovation drought moving closer, generic drug makers are looking to move up the value chain and pursue new sources of revenue, and of all the piles of pay dirt out there, biosimilars represent one of the closest things to an El Dorado, though regulations won’t take their final form for a while.


With the patent cliff and subsequent innovation drought moving closer, generic drug makers are looking to move up the value chain and pursue new sources of revenue, and of all the piles of pay dirt out there, biosimilars represent one of the closest things to an El Dorado, though regulations won’t take their final form for a while.


December 13, 2011

Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.

BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals has added four new executives, the company said.

Joseph Todisco has been appointed SVP global corporate strategy and business development. Previously serving as VP business development for Ranbaxy, Todisco will be responsible for the growth of Amneal's U.S. generics business and development of partnerships, mergers and acquisitions.

October 25, 2011

Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

HYDERABAD, India — Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

October 24, 2011

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.